Vall d’Hebron University Hospital hosted the signature of the collaboration agreement of a research project between the hospital (HUVH), its research institute (VHIR) and the company B. Braun Medical, S. A. to validate a new treatment for burns. The research project, called ‘Prospective and descriptive study of a cohort with Prontosan Wound Gel X, for the treatment of second-degree burns “Prontoburn”’, aims to assess the security profile of the product ‘Prontosan Wound Gel X’ in the recovery of second-degree burns affecting no more than the 15% of the body surface area, and to evaluate the evolution, recovery and tolerability of the burns after using this product.The scientific responsible of the research project and principal investigator is Dr. Joan Pere Barret Nerín, head of the Plastic Surgery and Burned Patients Service at HUVH and VHIR’s researcher. The team of the Burned Patients Unit at Vall d’Hebron has participated in many clinical and research studies, with the goal of validating and developing treatments for patients with different types of burns. As a result of these initiatives, the project ‘Prontosan Wound Gel X’ has been developed.The promoter of the study is Braun Medical, S.A., a company interested in collaborating with VHIR’s scientific goals and with the promotion of this product. During the project, researchers will evaluate the effectiveness of the treatment of cleaning and moisturizing the second-degree burns with prolihexanida, and it is expected that its effect will be similar to other antiseptic preparations but with the advantage of not entailing side effects. During the signing of the agreement, VHIR’s director, Dr. Joan Comella, showed his satisfaction and offered to Braun Vall d’Hebron as “their reference laboratory for practicing”. On the other hand, Jesús Donado-Mazarrón, Braun’s general manager in Spain, assured that “this will be the first of many agreements with this hospital”.For a year, this study will be carried out with 60 patients in the Burned Patients Unit of HUVH in Barcelona.